ciężkości COVID-19 za pomocą swoistego przeciwciała

Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby

 

Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or dying.

Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness danger issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 probability ratio (96.7% specificity).

The outcomes lay the groundwork for a brand new kind of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such data may information simpler therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely ailing sufferers.

Analysis of COVID-19 is quickly completed by means of a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness danger issue rating based mostly upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.

mat2tab
mat2tab

Human IGF-BP4 Recombinant Protein

100-200 20 µg
EUR 196.35
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Human IGF-BP4 Recombinant Protein

100-200S 5 µg
EUR 92.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF-BP4 Protein

PROTP22692-1 20ug
EUR 380.4
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Human IGF-BP4 Recombinant Protein Lyophilized

IHUIGFBP4RLY5UG each
EUR 341
Description: Human IGF-BP4 Recombinant Protein Lyophilized

Human IGF-BP4 Recombinant Protein Lyophilized

MBS8432291-INQUIRE INQUIRE Ask for price

IGF-BP4 Recombinant Protein

40-318-0005mg 0.005 mg
EUR 311.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

IGF-BP4 Recombinant Protein

40-318-002mg 0.02 mg
EUR 437.1
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

Recombinant Human IGF BP3

HEGFP-0903 5ug Ask for price

Recombinant Human IGF BP5

HEGFP-0905 5ug Ask for price

Recombinant Human IGF BP7

HEGFP-0907 5ug Ask for price

human anti-human IGF-1 mAb(6E)

E4A09K04-6E 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IGF-1 mAb(8D)

E4A09K04-8D 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

IRBAHURIPK1IGF18C100UL each
EUR 496
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

Human IGF-BP7

MBS691503-0005mg 0.005mg
EUR 300

Human IGF-BP7

MBS691503-0025mg 0.025mg
EUR 450

Human IGF-BP7

MBS691503-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP6

MBS691832-0005mg 0.005mg
EUR 300

Human IGF-BP6

MBS691832-002mg 0.02mg
EUR 450

Human IGF-BP6

MBS691832-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP3

MBS692057-0005mg 0.005mg
EUR 300

Human IGF-BP3

MBS692057-0025mg 0.025mg
EUR 450

Human IGF-BP3

MBS692057-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP2

MBS692085-0005mg 0.005mg
EUR 300

Human IGF-BP2

MBS692085-002mg 0.02mg
EUR 450

Human IGF-BP2

MBS692085-5x002mg 5x0.02mg
EUR 1725

Human IGF-BP1

MBS692092-0005mg 0.005mg
EUR 300

Human IGF-BP1

MBS692092-0025mg 0.025mg
EUR 450

Human IGF-BP1

MBS692092-5x0025mg 5x0.025mg
EUR 1725

Human IGF-BP5

MBS692152-0005mg 0.005mg
EUR 300

Human IGF-BP5

MBS692152-0025mg 0.025mg
EUR 450

Human IGF-BP5

MBS692152-5x0025mg 5x0.025mg
EUR 1725

Human IGF-1

MBS691641-01mg 0.1mg
EUR 300

Human IGF-1

MBS691641-05mg 0.5mg
EUR 450

Human IGF-1

MBS691641-5x05mg 5x0.5mg
EUR 1725

Human IGF-2

MBS691655-001mg 0.01mg
EUR 300

Human IGF-2

MBS691655-005mg 0.05mg
EUR 450

Human IGF-2

MBS691655-5x005mg 5x0.05mg
EUR 1725

IGF-BP3, Human

HY-P7020 10ug
EUR 280.8

IGF-BP5, Human

HY-P7021 50ug
EUR 721.2

IGF-BP3, human

RC216-12B3 5ug
EUR 125.26

Anti-Human IGF-BP1 Antibody

101-M457 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP2 Antibody

101-M458 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

101-M459 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

101-M461 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP6 Antibody

101-M462 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

101-M463 100 µg
EUR 399
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP3 Antibody

102-P144 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP5 Antibody

102-P232 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Anti-Human IGF-BP7 Antibody

102-P233 100 µg
EUR 245.7
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

IGF BP3 antibody

70R-IR022 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody

IGF BP5 antibody

70R-IR023 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody

IGF BP7 antibody

70R-IR024 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody

IGF BP7 antibody

MBS535700-005mg 0.05mg
EUR 465

IGF BP7 antibody

MBS535700-5x005mg 5x0.05mg
EUR 1945

IGF BP3 antibody

MBS535722-005mg 0.05mg
EUR 465

IGF BP3 antibody

MBS535722-5x005mg 5x0.05mg
EUR 1945

IGF BP5 antibody

MBS535907-005mg 0.05mg
EUR 465

IGF BP5 antibody

MBS535907-5x005mg 5x0.05mg
EUR 1945

IGF-1, Human

HY-P7018 10ug
EUR 129.6

IGF-2, Human

HY-P7019 100ug
EUR 432

IGF-1, human

RC216-12 1mg
EUR 451.5

IGF-1 (Human)

MBS352114-1Bottle 1Bottle
EUR 350

IGF-1 (Human)

MBS352114-5x1Bottle 5x1Bottle
EUR 1490

IGF-1 (Human)

MBS352116-01mL 0.1mL
EUR 450

IGF-1 (Human)

MBS352116-5x01mL 5x0.1mL
EUR 1950

IGF-2 (Human)

MBS352118-1Bottle 1Bottle
EUR 350

IGF-2 (Human)

MBS352118-5x1Bottle 5x1Bottle
EUR 1490

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.01 10ug
EUR 208
Description: Peptides & Proteins|Recombinant Proteins

Recombinant Human LR3 IGF-I/IGF-1

PH2031-.1 10X10ug
EUR 496
Description: Peptides & Proteins|Recombinant Proteins

Anti-Human IGF-1 Antibody

101-M454 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

101-M456 100 µg
EUR 399
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-1 Antibody

102-P28 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Anti-Human IGF-2 Antibody

102-P29 100 µg
EUR 245.7
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.

Antibody for Human IGF-1

SPC-699D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.

Antibody for Human IGF-1

SPC-699D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.

Antibody for Human IGF-1

SPC-699D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.

Antibody for Human IGF-1

SPC-699D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.

Antibody for Human IGF-1

SPC-699D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.

Antibody for Human IGF-1

SPC-699D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.

Antibody for Human IGF-1

SPC-699D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.

Antibody for Human IGF-1

SPC-699D-DY405 0.1mg
EUR 483.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.

Antibody for Human IGF-1

SPC-699D-DY488 0.1mg
EUR 471.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.

Antibody for Human IGF-1

SPC-699D-DY594 0.1mg
EUR 474
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594.

Antibody for Human IGF-1

SPC-699D-DY633 0.1mg
EUR 468
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633.

Antibody for Human IGF-1

SPC-699D-P594 0.1mg
EUR 488.4
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594.

Antibody for Human IGF-1

SPC-699D-STR 0.1mg
EUR 477.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin.

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS635918-005mg 0.05mg
EUR 495

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS635918-5x005mg 5x0.05mg
EUR 2075

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-001mg 0.01mg
EUR 390

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-005mg 0.05mg
EUR 540

Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2)

MBS650945-5x005mg 5x0.05mg
EUR 2275

Human IGF-I

GWB-4FCE40 0.1 mg Ask for price

Human IGF-I

MBS400113-INQUIRE INQUIRE Ask for price

Human IGF-I

MBS400117-01mg 0.1mg
EUR 170

Human IGF-I

MBS400117-05mg 0.5mg
EUR 235

Human IGF-I

MBS400117-10mg 10mg
EUR 1595

Human IGF-I

MBS400117-1mg 1mg
EUR 305

Human IGF-I

MBS400117-5mg 5mg
EUR 940

Human Salivary IGF(salivary IGF) ELISA Kit

QY-E05383 96T
EUR 433.2

Human IGF-I / IGF-II Panel, Antigen Standard: Pre-Mixed

SMX470 2 Plex
EUR 150

IGF-I, Human

E34M113H 20 μg
EUR 155
Description: Recombinant Human Cytotoxic T-lymphocyte Protein 4 is produced by our Mammalian expression system and the target gene encoding Lys36-Asp161 is expressed with a Flag tag at the C-terminus.

IGF-I, Human

MBS8575270-002mg 0.02mg
EUR 245

IGF-I, Human

MBS8575270-5x002mg 5x0.02mg
EUR 940

IGF-II, Human

E34M114H 5 μg
EUR 155

IGF-II, Human

MBS8575271-0005mg 0.005mg
EUR 245

IGF-II, Human

MBS8575271-5x0005mg 5x0.005mg
EUR 940

Human IGF-1 LR3

SP-89927-100 100 ug
EUR 270

Human IGF-1 LR3

MBS692296-02mg 0.2mg
EUR 300

Human IGF-1 LR3

MBS692296-1mg 1mg
EUR 450

Human IGF-1 LR3

MBS692296-5x1mg 5x1mg
EUR 1725

Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom

 

Background/goal: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Sufferers and strategies: Sera and knowledge from 79 sufferers have been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) have been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) have been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers have been assessed.

Outcomes: S100A9 ranges have been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations have been discovered between alarmin ranges and BVAS, FFS, and VDI.

Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.

Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków

 

Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).

The sufferers have been two ladies from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers introduced with RP-ILD with none medical options of myositis and succumbed to their sickness regardless of aggressive medical remedy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.

Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro

 

Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, significantly for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and medical impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, might be a better option and negate the necessity for an in vivo efficiency take a look at. These immunochemical strategies require not less than one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the great characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for growth of an in vitro efficiency immunoassay.

We’ve got assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to help prior in vivo efficiency knowledge that was accessible for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to determine pairs of antibodies that might be deployed in a sandwich immunoassay format. Not all characterisation checks supplied proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay growth.

Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych

Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic situations described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case experiences and investigations concerning anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the medical knowledge of three anti-GAD65 antibody-positive sufferers to discover the range and medical options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.

Strategies: The medical knowledge of a sequence of three sufferers optimistic for anti-GAD65 antibody have been retrospectively analyzed. GAD65 antibodies have been decided in serum and CSF utilizing a cell-based assay.

Outcomes: All three sufferers have been feminine, and the onset ages have been four years and 9 months, 6 years, and 16 years outdated. Their medical phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The medical signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers acquired immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.

Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nonetheless, sufferers with limbic encephalitis typically have refractory epilepsy within the power part and have a poor long-term end result.

CXCL7 (48-109), Mouse

MBS8575412-0005mg 0.005mg
EUR 245

CXCL7 (48-109), Mouse

MBS8575412-5x0005mg 5x0.005mg
EUR 940

Mouse CXCL7 ELISA Kit

MBS8291406-5x96Tests 5x96Tests
EUR 2755

Mouse CXCL7 ELISA Kit

MBS8291406-96Tests 96Tests
EUR 620

Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7)

MBS140066-05mg 0.5mg
EUR 440

Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7)

MBS140066-1mg 1mg
EUR 600

Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7)

MBS140066-5x1mg 5x1mg
EUR 2375

Rat Monoclonal anti-mouse CXCL7

mAP-0211 100ug
EUR 250

Anti-Human CXCL7 Antibody

101-M357 100 µg
EUR 399
Description: NAP-2 or CXCL7 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7.6 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the “ELR” motif common to CXC chemokines that bind to CXCR1 and CXCR2.

CXCL7 (PPBP) mouse monoclonal antibody, Azide Free

PM1210P 500 µg Ask for price

Mouse PPBP/CXCL7 PicoKine ELISA Kit

EK0730 96 wells
EUR 510
Description: For Quantitative Detection of mouse CXCL7 in cell culture supernates, serum and plasma (heparin, EDTA).

Mouse PPBP/CXCL7 PicoKine ELISA Kit

MBS1751073-5x96StripWells 5x96-Strip-Wells
EUR 2755

Mouse PPBP/CXCL7 PicoKine ELISA Kit

MBS1751073-96StripWells 96-Strip-Wells
EUR 600

Mouse CXCL7/Thymus Chemokine-1 ELISA Kit

E16ME0075 96T
EUR 833.33

Anti-Human NAP-2 (CXCL7)

MBS550706-01mg 0.1mg
EUR 260

Anti-Human NAP-2 (CXCL7)

MBS550706-02mg 0.2mg
EUR 335

Mouse beta Thromboglobulin (CXCL7/bTG) CLIA Kit

20-abx491403
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Recombinant Mouse CXCL7 (40-113) protein(N-His)(active)

PKSM041515-100ug 100ug
EUR 739
Description: Mouse

Recombinant Mouse CXCL7 (40-113) protein(N-His)(active)

PKSM041515-20ug 20ug
EUR 249
Description: Mouse

Recombinant Mouse CXCL7 (48-109) protein(N-His)(active)

PKSM041516-100ug 100ug
EUR 739
Description: Mouse

Recombinant Mouse CXCL7 (48-109) protein(N-His)(active)

PKSM041516-20ug 20ug
EUR 249
Description: Mouse

Recombinant Mouse CXCL7 (40-113) protein (N-His)(active)

MBS2569986-002mg 0.02mg
EUR 270

Recombinant Mouse CXCL7 (40-113) protein (N-His)(active)

MBS2569986-01mg 0.1mg
EUR 690

Recombinant Mouse CXCL7 (40-113) protein (N-His)(active)

MBS2569986-5x01mg 5x0.1mg
EUR 3105

Recombinant Mouse CXCL7 (48-109) protein (N-His)(active)

MBS2569987-002mg 0.02mg
EUR 270

Recombinant Mouse CXCL7 (48-109) protein (N-His)(active)

MBS2569987-01mg 0.1mg
EUR 690

Recombinant Mouse CXCL7 (48-109) protein (N-His)(active)

MBS2569987-5x01mg 5x0.1mg
EUR 3105

Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT

E2614Mo-1096T 10*96T
EUR 4122

Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT

E2614Mo-48wells 48 wells
EUR 300

Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT

E2614Mo-596T 5*96T
EUR 2061

Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT

E2614Mo-96wells 96 wells
EUR 458

Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit

MBS1603801-10x96StripWells 10x96-Strip-Wells
EUR 3955

Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit

MBS1603801-48StripWells 48-Strip-Wells
EUR 305

Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit

MBS1603801-5x96StripWells 5x96-Strip-Wells
EUR 2005

Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit

MBS1603801-96StripWells 96-Strip-Wells
EUR 475

Mouse CXC-Chemokine Ligand 7, CXCL7 GENLISA ELISA

KLM2614 1 x 96 wells
EUR 341

Anti-Human NAP-2 (CXCL7) Antibody

101-M81 500 µg
EUR 246.75
Description: NAP-2 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7-8 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the “ELR” motif common to CXC chemokines that bind to CXCR1 and CXCR2.

Anti-Human NAP-2 (CXCL7) Antibody

102-P191G 100 µg
EUR 245.7
Description: Neutrophil Activating Peptide 2 (NAP2), Connective Tissue Activating Protein III (CTAPIII) and βthrombogulin ( βTG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. NAP2 is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL8 and the GRO proteins, NAP2 has been shown to bind CXCR2 and to chemoattract and activate neutrophils. Although CTAPIII, βTG and PBP represent aminoterminal extended variants of NAP 2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP2 activity. It has been shown that the additional aminoterminal residues of CTAP III masks the critical ELR receptor binding domain that is exposed on NAP2 and may account for lack of NAP2 activity.

Anti-Human NAP-2 (CXCL7) Antibody

102-P71 100 µg
EUR 245.7
Description: NAP-2 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7-8 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the “ELR” motif common to CXC chemokines that bind to CXCR1 and CXCR2.

Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit

IMSPPBPKT each
EUR 702
Description: Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit

Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit

MBS8420837-1Kit 1Kit
EUR 755

Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit

MBS8420837-5x1Kit 5x1Kit
EUR 3455

CXCL7/PBP Antibody

DF6695 200ul
EUR 420

CXCL7/PBP Antibody

DF6695-100ul 100ul
EUR 280

CXCL7/PBP Antibody

DF6695-200ul 200ul
EUR 350

CXCL7 Protein, Mouse, Recombinant (aa 40-113, His Tag)

MBS8122558-005mg 0.05mg
EUR 395

CXCL7 Protein, Mouse, Recombinant (aa 40-113, His Tag)

MBS8122558-5x005mg 5x0.05mg
EUR 1635

Human CXCL7 Antibody

32852-05111 150 ug
EUR 215

Anti-Human PPBP/CXCL7/NAP-2 Antibody

MBS1569895-01mg 0.1mg
EUR 375

Anti-Human PPBP/CXCL7/NAP-2 Antibody

MBS1569895-5x01mg 5x0.1mg
EUR 1390

CXCL7,Human

E34M164H 5 μg
EUR 155

CXCL7, Human

MBS8575321-0005mg 0.005mg
EUR 245

CXCL7, Human

MBS8575321-5x0005mg 5x0.005mg
EUR 940

Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit

RE3404M-48wells 48 wells
EUR 116.55

Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit

RE3404M-96wells 96 wells
EUR 161.55

Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit

RE3404M-48wellsplate 48-wells plate
EUR 126

Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit

RE3404M-96wellsplate 96-wells plate
EUR 180

Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-EL-M1269-24Tests 24 Tests
EUR 150
Description: Sandwich

Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-EL-M1269-48Tests 48 Tests
EUR 487
Description: Sandwich

Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-EL-M1269-96Tests 96 Tests
EUR 609
Description: Sandwich

Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-EL-M1269-96Tests10 96 Tests *10
EUR 6090
Description: Sandwich

Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-EL-M1269-96Tests5 96 Tests *5
EUR 3045
Description: Sandwich

Sheep Polyclonal anti-Human CXCL7 (NAP-2)

hAP-5825 50ug
EUR 400

ELISA kit for Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)

E-EL-M1269 1 plate of 96 wells
EUR 640.8
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant

NAP-2 Antibody / CXCL7

R31872 100 ug
EUR 356.15
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP-2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity.

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKN43824-48T 48T
EUR 350.42

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKN43824-5x96T 5x96T
EUR 2377.85

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKN43824-96T 96T
EUR 500.6

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKU02713-48T 48T
EUR 514.08

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKU02713-5x96T 5x96T
EUR 3488.4

Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit

EKU02713-96T 96T
EUR 734.4

CXCL7/NAP-2

PR27118 2 ug
EUR 229.2

CXCL7/NAP-2

PR27118-B each
EUR 184.5

Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-UNEL-M0083-24Tests 24 Tests Ask for price
Description: Sandwich

Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-UNEL-M0083-48Tests 48 Tests
EUR 958
Description: Sandwich

Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-UNEL-M0083-96Tests 96 Tests
EUR 399
Description: Sandwich

Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-UNEL-M0083-96Tests10 96 Tests *10
EUR 3990
Description: Sandwich

Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit

E-UNEL-M0083-96Tests5 96 Tests *5
EUR 1995
Description: Sandwich

Human NAP2(CXCL7)

90222-A 2 µg
EUR 130
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli.

Human NAP2(CXCL7)

90222-B 10 µg
EUR 205
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli.

CXCL7 Rabbit pAb

E2160414 100ul
EUR 225
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Uncoated Mouse betaTG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) ELISA Kit

MBS2571903-15x96Tests3xMBS2571967AncillaryKit 15x96Tests+3xMBS2571967(AncillaryKit)
EUR 1565

Uncoated Mouse betaTG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) ELISA Kit

MBS2571903-5x96TestsMBS2571967AncillaryKit 5x96Tests+MBS2571967(AncillaryKit)
EUR 670

Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit

MBS7615137-10x96StripWells 10x96-Strip-Wells
EUR 3900

Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit

MBS7615137-48StripWells 48-Strip-Wells
EUR 340

Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit

MBS7615137-5x96StripWells 5x96-Strip-Wells
EUR 2045

Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit

MBS7615137-96StripWells 96-Strip-Wells
EUR 455

Recombinant Rat CXCL7

MBS7611197-005mg 0.05mg
EUR 345

Recombinant Rat CXCL7

MBS7611197-02mg 0.2mg
EUR 635

Recombinant Rat CXCL7

MBS7611197-1mg 1mg
EUR 1800

Dodaj komentarz